Table 2.

Subsequent osteoporotic fracture rate and time to onset

	FREEDOM analysis (3 years)		FREEDOM + Extension analysis (10 years)
	Placebo N = 438	Denosumab N = 272	Combined denosumab N = 794
Subject-years of follow-up	532.3	357.2	2497.5
Subjects with ≥ 1 subsequent fracture, n (%)	54 (12.3)	24 (8.8)	144 (18.1)
Exposure-adjusted subsequent fracture rate, per 100 subject-years	10.1	6.7	5.8
Median time to subsequent fracture since first incident fracture among subjects with ≥ 1 subsequent fracture, years	1.0	0.8	1.9

N subjects who received ≥ 2 doses of investigational product, had an osteoporotic fracture on treatment, and remained on study post-fracture, n number of subjects